The Week in Review: November 10 – November 17, 2017

Friday, November 17, 2017 News Recap: AASLD 2017 HCV Clinical Guidelines and Patient Management highlights from The Liver Meeting 2017. Thanks to the Canadian Society for International Health we are able to share this excellent presentation, by Dr. Curtis Cooper, on highlights from AASLD 2017. Liver Cancer Global Perspectives on Hepatocellular Carcinoma.  Be sure to check out this excellent article! A panel of international oncology experts rece...

Nivolumab improves outcomes in liver cancer study

The median overall survival was 15.0 and 15.6 months in the two sorafenib-experienced groups. In comparison, people who switched from sorafenib to a recently approved similar drug, regorafenib (Stivarga), had a median survival of about 11 months. The median survival for the sorafenib-naive group could not be determined because a majority of patients were still alive, but this was projected to be 28.6 months. Nivolumab (Opdivo), a PD-1 checkpoint inhibitor